Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 4:36 PM ET


Company Overview of Opsona Therapeutics Limited

Company Overview

Opsona Therapeutics Limited operates as a clinical stage biopharmaceutical company. The company primarily focuses on developing drugs for the treatment of autoimmune/inflammatory diseases and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease, and atherosclerosis. Its portfolio includes OPN-305, a monoclonal/humanized antibody that reduces pro-inflammatory cytokine production associated with heart and kidney diseases, as well as capable of dampening down the body’s immune response to a donated kidney. The company’s development portfolio includes IL-1ß inhibitors. Opsona Therapeutics Limited was founded in 2004 and is based in Dublin, Ireland.

Second Floor

Ashford House

Tara Street

Dublin,  2


Founded in 2004


353 1 677 0223


353 1 677 8949

Key Executives for Opsona Therapeutics Limited

Chief Executive Officer
Age: 54
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Scientific Advisor
Age: 59
Co-Founder, Chief Scientific Officer and Director
Finance Director
Age: 50
Compensation as of Fiscal Year 2015.

Opsona Therapeutics Limited Key Developments

Opsona Therapeutics Limited Presents at BioEquity Europe 2015, May-20-2015 11:20 AM

Opsona Therapeutics Limited Presents at BioEquity Europe 2015, May-20-2015 11:20 AM. Venue: InterContinental Vienna, Vienna, Austria.

Opsona Therapeutics Limited Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM

Opsona Therapeutics Limited Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

Opsona Therapeutics Ltd. Commences Part B of Phase II Study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor Renal Transplant Recipients At High Risk of Early Graft Dysfunction

Opsona Therapeutics Ltd. announced the continuation of its double-blind renal transplant study by the initiation of Part B of its adaptive phase II clinical trial in Extended Criteria Donors (ECD) renal transplant recipients at high risk of early graft dysfunction with its lead drug candidate OPN-305. Based on the completion of Part A of this double blind study, OPN-305 was well tolerated and deemed to be safe by the data and safety monitoring board across all dose groups with no evidence of increased risk of infection in these highly immuno-suppressed patients. The company is proceeding with Part B in a modified patient population evaluating ECD-only recipients. ECD kidneys make up the large pool of the cadaveric donor population. Currently up to 45% of ECD kidneys are discarded resulting in a significant deficit in supply versus demand. OPN-305 has the opportunity to turn borderline non-transplantable organs into viable kidneys and functioning grafts resulting in fewer ECD discards, driving an overall increase in the number of deceased donor transplants.

Similar Private Companies By Industry

Company Name Region
Nuritas, Ltd. Europe
Grifols Worldwide Operations Ltd. Europe
Premier Biomaterials Ltd. Europe
Genable Technologies Ltd. Europe
Elan Corp Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Opsona Therapeutics Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at